Endostar
Trials 121 · started per year
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT04472806 Background | Jun 2020 → Jun 2022 | mucosal melanoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03649945 Comparator | Nov 2018 → Nov 2020 | esophageal cancer | First Affiliated Hospital of Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT01549093 Comparator | Aug 2011 → Jul 2016 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04914598 Comparator | Jul 2021 → Feb 2025 overdue | pleural disorder | Jiangsu Simcere Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02748772 Comparator | Jan 2016 → Dec 2017 | colorectal neoplasm | The First People's Hospital of Hefei | Unknown | No outcome recorded |
| Phase 3 | NCT00576914 Comparator | Jun 2007 → Jun 2012 | non-small cell lung carcinoma | Chinese Academy of Sciences | Unknown | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 133 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Endostar | “This single-arm pilot study tries to invesitgate how well giving icotinib with rh-endostatin (Endostar®) works in treating patients with advanced stage non-small cell lung...” NCT02375022 ↗86“Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination...” NCT03577392 ↗ “The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer...” NCT02283476 ↗ “This phase II trial evaluated the efficacy and safety of a soluble and stable rhES (Endostar) plus dacarbazine in patients with metastatic melanomas that contains no mutations...” PMID 23670576 ↗ May 2013 “Concurrently, recombinant human endostatin (Endostar) induces tumor vascular normalization and alleviates immunosuppression by inhibiting regulatory T cells (Tregs).” PMID 42291342 ↗ May 2026 “Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks.” NCT03622827 ↗ “Camrelizumab (SHR-1210) Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous Non-small Cell Lung Cancer (NSCLC)” NCT04303130 ↗ “Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma” NCT06562673 ↗ “A Prospective, Singal-arm Clinical Study of Recombinant Human Endostatin (ENDOSTAR) Combined With Carboplatin and Vincristine” NCT04659421 ↗ “Recombinant Human Endostatin Injection (Endostar),210mg was pumped intravenously for 3 consecutive days” NCT06617936 ↗ “Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.” NCT01211002 ↗ “human recombinant endostatin (endostar) for breast cancer patients” NCT00604435 ↗ “Rh-Endostatin (Endostar®) Continuous Intravenous Infusion” NCT03706703 ↗ “with or without human recombinant endostatin (endostar)” NCT01479036 ↗ “recombinant human endostatin (endostar)” NCT01915134 ↗ “human recombinant endostatin (endostar)” NCT01907529 ↗ “Recombinant human endostatin (Endostar)” NCT04613284 ↗ |
| Known as | Endostar (a recombinant human endostatin) | “Endostar (a recombinant human endostatin)” NCT00853684 ↗ |
| Known as | Endostat | “recombinant human endostatin (Endostat)” NCT01310478 ↗ |
| Known as | Endostatin | “Endostar is a recombinant product of endostatin, which is an endogenous inhibitor of angiogenesis.” NCT02865304 ↗21“nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d” NCT03917069 ↗ “Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W” NCT05387681 ↗ “Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib” NCT03461185 ↗ “human recombinant endostatin (endostar)” NCT01907529 ↗ |
| Known as | Endostatin, Simcere-Medgenn (No. S20050088) | “Endostatin, Simcere-Medgenn (No. S20050088)” NCT01479036 ↗ |
| Known as | human recombinant endostatin | “human recombinant endostatin (endostar) for breast cancer patients” NCT00604435 ↗1“Endostar (human recombinant endostatin)” NCT02513355 ↗ |
| Known as | recombinant human endostatin | “This study is aim to observe the safety and efficacy of the combination of an anti-angiogenic drug recombinant human-endostatin with EGFR TKI ,to find out a new strategy which...” NCT03008109 ↗38“NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid)...” PMID 41014160 ↗ Nov 2025 “The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.” NCT03577392 ↗ “Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks.” NCT03622827 ↗ “To evaluate the effectiveness, safety and tolerability of Endostar (recombinant human endostatin) combined with AI chemotherapy” NCT04699214 ↗ “Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.” NCT02513342 ↗ “Recombinant human endostatin (rh-ES) is an endogenous broad-spectrum angiogenesis inhibitor” NCT04659421 ↗ “Endostar ® (recombinant human endostatin) continuous intravenous infusion” NCT02749526 ↗ “recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles.” NCT00657423 ↗ “recombinant human endostatin (Rh-endostatin)” PMID 35380726 ↗ Apr 2022 “recombinant human endostatin (endostatin)” NCT05551247 ↗ “endostar (recombinant human endostatin)” NCT00842491 ↗ “Endostar (Recombinant Human Endostatin)” NCT00813449 ↗ “recombinant human endostatin (Endostar)” NCT05574998 ↗ “Recombinant human endostatin (Endostar)” NCT06965231 ↗ “Recombinant Human Endostatin(Endostar)” NCT00813137 ↗ |
| Known as | Recombinant Human Endostatin Injection | “Recombinant Human Endostatin Injection：210 mg, intravenous infusion for 72 hours, once every three weeks cycle” NCT06279754 ↗1“Endostar(Recombinant Human Endostatin Injection)” NCT00708812 ↗ |
| Known as | rh recombinant endostatin | “Endostar(rh recombinant endostatin) plus Docetaxel” NCT00813332 ↗ |
| Known as | rh-endostatin | “This single-arm pilot study tries to invesitgate how well giving icotinib with rh-endostatin (Endostar®) works in treating patients with advanced stage non-small cell lung...” NCT02375022 ↗13“NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid)...” PMID 41014160 ↗ Nov 2025 “The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer...” NCT02283476 ↗ “To further assess the efficacy and safety of recombinant human endostatin (rh-endostatin), a Phase III, multicenter, prospective, randomized, controlled clinical trial was conducted.” PMID 29238974 ↗ Dec 2017 “Endostar™ (rh-endostatin, YH-16) is a new recombinant human endostatin developed by Medgenn Bioengineering Co. Ltd., Yantai, Shandong, P.R.China.” PMID 21108883 ↗ Aug 2005 “Rh-Endostatin (Endostar; Simcere Pharmaceutical Co., Ltd, JiangSu,China) is a humanized recombinant endostatin” NCT01529164 ↗ “Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in China.” PMID 23693018 ↗ May 2013 “recombinant human endostatin (Rh-endostatin) plus irinotecan/cisplatin as second-line treatment” PMID 35380726 ↗ Apr 2022 “Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d” NCT03208335 ↗ “Rh-Endostatin (Endostar®) Continuous Intravenous Infusion” NCT03706703 ↗ |
| Known as | Rh-endostatin Injection | “Endostar® (Rh-endostatin Injection) may have anti-tumor activity by against vascular endothelial growth factor for initial treatment.” NCT00912392 ↗ |
| Known as | rh-ES | “However, efficacy of recombinant human endostatin (rhES) in clinical trials is controversial, and application of rhES in treatment of metastatic melanoma awaits further investigations.” PMID 23670576 ↗ May 20133“Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.” NCT05278715 ↗ “Recombinant human endostatin (rh-ES) is an endogenous broad-spectrum angiogenesis inhibitor” NCT04659421 ↗ “Recombinant human endostatin (rh-ES) is an endogenous broad-spectrum angiogenesis inhibitor” NCT04267978 ↗ |
| Known as | YH-16 | “Endostar™ (rh-endostatin, YH-16) is a new recombinant human endostatin developed by Medgenn Bioengineering Co. Ltd., Yantai, Shandong, P.R.China.” PMID 21108883 ↗ Aug 2005 |
| Action | Inhibit | “a inhibitor of angiogenesis” NCT00595972 ↗ |
| Modality | Protein / enzyme biologic | “Human Recombinant Endostatin” NCT00004229 ↗ |
| Route | Intravenous | “Patients receive endostatin IV daily for 4 weeks.” NCT00004229 ↗ |